Clinical Monographs

What Do 2026 Obesity Analyses Reveal About Retatrutide's Efficacy and Safety Risk-Benefit Profile?

Retatrutide (LY3437943) is a triple GLP-1/GIP/glucagon receptor agonist in Phase 3 development. It demonstrated up to 24.2% mean body-weight reduction at 48 weeks in its pivotal Phase 2 trial. Emerging 2026 analyses confirm robust efficacy but flag dose-dependent gastrointestinal adverse events and a persistent resting heart-rate elevation as the primary safety signals requiring ongoing risk-benefit evaluation.